# Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

> **NCT07651319** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 30 (estimated)

## Conditions studied

- Alzheimer Dementia (AD)

## Interventions

- **DRUG:** IL-2 (Aldesleukin)
- **DRUG:** Semaglutide Plus IL-2
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07651319
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-06
- **Final completion:** 2029-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07651319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07651319, "Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07651319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*